Phathom Pharmaceuticals Signals Strong Growth on Earnings Call

Phathom Pharmaceuticals, Inc. ((PHAT)) has held its Q1 earnings call. Read on for the main highlights of the call.

Phathom Pharmaceuticals’ latest earnings call struck a largely upbeat tone, underscoring powerful year‑over‑year growth and accelerating prescription trends even as near‑term revenue came in slightly below internal expectations. Management emphasized strong commercial execution, disciplined spending, and a solid cash position, arguing that these positives outweigh current headwinds in pricing, mix, and seasonality.

Explosive Revenue Growth But Limited Sequential Upside

Net revenues reached $58.3 million in Q1 2026, more than doubling the $28.5 million recorded a year earlier as VOQUEZNA continued to scale. Sequential growth versus Q4 2025 was modest at roughly 1%, yet management chose to maintain its full‑year revenue guidance range of $320 million to $345 million, signaling confidence in a stronger back half.

VOQUEZNA Prescriptions Surge as Market Penetration Deepens

Prescription data showed meaningful traction, with approximately 268,000 VOQUEZNA prescriptions filled in Q1 and about 1.35 million filled through April 17. Covered prescriptions grew about 91% year‑over‑year and total prescriptions climbed roughly 115%, with two of the first three weeks of April setting new all‑time highs for covered script volume.

Gastroenterologists Drive High New‑to‑Brand Conversion

Phathom highlighted strong new patient capture among gastroenterologists, where the top 300 writers reached about 45% new‑to‑brand prescription share versus PPIs in Q1. Across the top 3,000 GI writers, cumulative NBRx share now exceeds 30%, and covered NBRx rose around 11% compared with Q4 2025, underscoring growing physician confidence.

Sales Force Expansion Underpins Commercial Execution

The company completed a significant sales expansion, adding nearly 50 new representatives and entering Q2 with more than 290 reps fully aligned. Management expects this larger field footprint to deepen coverage in gastroenterology, increase healthcare‑provider engagement, and support sustained prescription and market share gains through 2026.

Strong Gross Margin and Favorable Gross‑to‑Net in Q1

Phathom reported an approximately 80% gross margin in Q1, supporting the long‑term profitability case for VOQUEZNA. The gross‑to‑net discount landed at the low end of the company’s 55% to 59% guidance range, helped by favorable channel mix in the quarter, although management cautioned that this metric can fluctuate from period to period.

Cost Discipline Drives Sharply Lower Cash Operating Spend

Cash operating expenses, excluding stock‑based compensation, totaled $56.2 million in Q1, reflecting a reduction of about 43% versus Q1 2025. Management framed this decline as evidence of tight expense control and a more efficient commercial model, even as it continues to invest in field force growth and development programs.

Solid Cash Position and Conservative Cash Usage

Net cash usage from operations was roughly $15 million in Q1, and Phathom ended the quarter with about $181 million in cash and cash equivalents. The company believes this balance, combined with growing operating cash generation, should allow it to meet obligations without raising additional capital, a key point for equity investors.

Clinical Pipeline Advances With EoE Trial Ahead of Plan

Beyond the commercial story, Phathom’s Phase II trial in eosinophilic esophagitis is enrolling ahead of schedule, pointing to operational strength in R&D. Management now expects topline data in late Q4 2026 or early Q1 2027, framing EoE as a potential future indication that could expand VOQUEZNA’s label and long‑term revenue opportunity.

Improved Data Visibility After Resolving IQVIA Reporting Gap

The company noted that an incremental IQVIA reporting gap flagged on the prior call was resolved by mid‑March, and current TRx figures now capture those previously missing prescriptions. This fix should give management and investors better visibility into underlying prescribing trends and reduce noise in future volume comparisons.

Q1 Revenue Light Versus Internal Targets Amid Seasonality

Despite strong year‑over‑year metrics, management acknowledged that Q1 revenue was somewhat below its internal expectations, citing typical market access seasonality, a winter storm impact, and the timing of new rep deployment. These factors, combined with only about 1% sequential growth, underscore some short‑term volatility in the ramp.

Near‑Term Operating Loss as Profitability Inflection Approaches

Phathom posted a loss from operations of roughly $9.9 million in Q1 on an ex‑stock‑based compensation basis, reflecting continued investment ahead of full earnings leverage. Management reiterated that it remains on a path to reach operating profitability later this year, positioning current losses as transitional rather than structural.

Persistently High Gross‑to‑Net Discount a Structural Drag

The company maintained guidance for a gross‑to‑net discount of 55% to 59% for 2026, acknowledging this remains a major headwind that materially compresses net revenue. Shifts in channel mix can move quarterly outcomes within that range, adding some unpredictability to near‑term reported sales even as underlying prescription volumes grow.

Large Cash‑Pay Component Adds Mix Volatility

In Q1, roughly 100,000 of the approximately 268,000 prescriptions, or about 37%, were cash‑pay, with about 63% covered by insurance. Management attributed part of this spike to deductible seasonality, but the large cash‑pay portion introduces additional variability in reimbursement, gross‑to‑net, and ultimately realized revenue.

Back‑Half Weighted Revenue Profile Raises Execution Risk

Phathom reaffirmed that 2026 revenue will be heavily weighted to the second half of the year, implying that much of the growth and margin expansion is still ahead. While prescription momentum to date supports this outlook, it also concentrates execution risk if trends soften, making upcoming quarters particularly important for investors to watch.

Future Competition Clouds Long‑Term P‑CAB Landscape

Management acknowledged the potential entry of a second P‑CAB, Tegoprazan, into the U.S. market in 2027, which could alter competitive dynamics. Phathom believes VOQUEZNA’s data package and first‑mover adoption create a durable edge, but investors must factor in added uncertainty around future pricing and market share.

Guidance and Profitability Milestones Define the Road Map

Phathom maintained its full‑year 2026 outlook, guiding to net revenues of $320 million to $345 million, a gross‑to‑net discount of 55% to 59%, and gross margin around 80%. The company expects cash operating expenses of $235 million to $255 million, a modest OpEx step‑up in Q2, and targets operating profitability excluding stock‑based compensation by Q3, full‑year 2026 profitability, and positive cash flow in 2027.

Phathom’s earnings call painted the picture of a high‑growth GI franchise moving toward profitability, supported by strong VOQUEZNA adoption, expanding physician uptake, and tight cost control. While high gross‑to‑net discounts, a sizable cash‑pay mix, and looming competition introduce risk, management’s reaffirmed guidance and cash runway should keep the story firmly on investors’ radar this year.